Prosaposin, a regulator of estrogen receptor alpha, promotes breast cancer growth

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1820-1825

  Wu, Yihong ^a,b   Sun, Linlin ^a,b   Zou, Weiying ^a,b   Xu, Jiejie ^a,b   Liu, Haiou ^a   Wang, Wenzhong ^a   Yun, Xiaojing ^a,b   Gu, Jianxin ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ESTROGEN RECEPTOR ALPHA; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSAPOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PROTEIN TRANSPORT; REAL-TIME POLYMERASE CHAIN REACTION; SAPOSINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867230216     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02374.x     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005; 67: 335-76.
3. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
4. Liao DZ, Pantazis CG, Hou X et al. Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 1998; 19: 2173-80.
5. Hilakivi-Clarke L, Cho E, Cabanes A et al. Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res 2002; 8: 3601-10.
6. Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 2000; 5: 271-81.
7. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133-40.
8. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 2004; 15: 316-23.
9. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004; 96: 218-28.
10. Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003; 22: 7316-39.
11. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004; 18: 1859-75.
12. Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007; 26: 4106-14.
13. Igdoura SA, Rasky A, Morales CR. Trafficking of sulfated glycoprotein-1 (prosaposin) to lysosomes or to the extracellular space in rat Sertoli cells. Cell Tissue Res 1996; 283: 385-94.
14. O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991; 5: 301-8.
15. Kishimoto Y, Hiraiwa M, O'Brien JS. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res 1992; 33: 1255-67.
16. Hineno T, Sano A, Kondoh K, Ueno S, Kakimoto Y, Yoshida K. Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 1991; 176: 668-74.
17. Fu Q, Carson GS, Hiraiwa M, Grafe M, Kishimoto Y, O'Brien JS. Occurrence of prosaposin as a neuronal surface membrane component. J Mol Neurosci 1994; 5: 59-67.
18. Elleder M, Jerabkova M, Befekadu A et al. Prosaposin deficiency - a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics 2005; 36: 171-80.
19. Fujita N, Suzuki K, Vanier MT et al. Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 1996; 5: 711-25.
20. Morales CR, Zhao Q, El-Alfy M, Suzuki K. Targeted disruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J Androl 2000; 21: 765-75.
21. Misasi R, Sorice M, Di Marzio L et al. Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase. FASEB J 2001; 15: 467-74.
22. Misasi R, Garofalo T, Di Marzio L et al. Prosaposin: a new player in cell death prevention of U937 monocytic cells. Exp Cell Res 2004; 298: 38-47.
23. Koochekpour S, Zhuang YJ, Beroukhim R et al. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosom Cancer 2005; 44: 351-64.
24. Koochekpour S, Lee TJ, Wang R et al. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Prostate 2007; 67: 178-89.
25. Koochekpour S, Hu S, Vellasco-Gonzalez C et al. Serum prosaposin levels are increased in patients with advanced prostate cancer. Prostate 2012; 72: 253-69.
26. Patton S, Carson GS, Hiraiwa M, O'Brien JS, Sano A. Prosaposin, a neurotrophic factor: presence and properties in milk. J Dairy Sci 1997; 80: 264-72.
27. Kondoh K, Hineno T, Sano A, Kakimoto Y. Isolation and characterization of prosaposin from human milk. Biochem Biophys Res Commun 1991; 181: 286-92.
28. Campana WM, O'Brien JS, Hiraiwa M, Patton S. Secretion of prosaposin, a multifunctional protein, by breast cancer cells. Biochim Biophys Acta 1999; 1427: 392-400.
29. Jiang J, Wei Y, Shen J et al. Functional interaction of E1AF and Sp1 in glioma invasion. Mol Cell Biol 2007; 27: 8770-82.
30. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-83.
31. Morales CR, Zhao Q, Lefrancois S, Ham D. Role of prosaposin in the male reproductive system: effect of prosaposin inactivation on the testis, epididymis, prostate, and seminal vesicles. Arch Androl 2000; 44: 173-86.
32. Hu S, Delorme N, Liu Z et al. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol Cancer 2010; 9: 30.
33. Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am J Physiol Endocrinol Metab 2002; 282: E891-8.
34. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D. CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. Genes Dev 2010; 24: 708-19.
35. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21: 4000-8.
36. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12(Suppl 1): S37-46.
37. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24: 85-95.